Delivery Order SPE2DB24D9315-SPE2DB26FFWGE
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $82,920.65 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Stelara 90mg/mL syringes. This firm fixed-price delivery order, issued on October 24, 2025, represents one of numerous pharmaceutical supply orders placed with DMS Pharmaceutical Group under the DLA's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V)...
- The Defense Logistics Agency issued a delivery order valued at $16,249.95 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Stelara 90 mg/mL syringes. The contract was awarded on October 21, 2025, with an ultimate completion date of November 12, 2025, under a firm fixed-price arrangement with no set-aside designation. This delivery order was issued pursuant to DMS Pharmaceutical Group's Indefinite...
- The Defense Logistics Agency's Medical Supply Chain division awarded a $81,249.75 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Stelara 90 mg/mL syringes. The delivery order, issued on October 17, 2025, carries an ultimate completion date of November 7, 2025, and was awarded without a set-aside designation, demonstrating the contractor's competitive capability in...
- The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $7,730.52 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Stelara 130 mg/26 mL vials. The delivery order, issued on October 24, 2025, with an ultimate completion date of November 17, 2025, carries no set-aside designation, indicating the vendor competed in unrestricted federal procurement. This award represents one of...
- The Defense Logistics Agency issued a delivery order valued at approximately $97.5K to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Stelara 90 mg/mL syringes. This firm fixed-price delivery order, awarded on October 23, 2025, represents a direct purchase without set-aside designation, demonstrating DMS Pharmaceutical Group's competitive capability in unrestricted federal pharmaceutical procurement. The...
- The Defense Logistics Agency awarded a delivery order valued at $48,749.85 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Stelara 90 mg/ml syringes. This firm fixed-price delivery order, issued on October 27, 2025, with an ultimate completion date of November 18, 2025, represents a small individual purchase within a larger pharmaceutical supply relationship. The award carries no set-aside...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $16,249.95 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Stelara 90 mg/ml syringes. The contract, designated as a firm fixed-price delivery order, was awarded on September 15, 2025, with an ultimate completion date of October 6, 2025. This delivery order was issued without a set-aside designation, allowing DMS Pharmaceutical Group to...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $16,154.36 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Stelara 90 mg/ml syringes. This firm fixed-price delivery order, issued on September 24, 2025, with an ultimate completion date of October 16, 2025, carries no set-aside designation. The award represents a continuation of DMS Pharmaceutical Group's role as a critical supplier...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, was awarded a firm fixed-price delivery order valued at $33,168.26 by the Defense Logistics Agency for STELARA 90 mg/mL syringes. The award, issued on October 23, 2025, with an ultimate completion date of November 14, 2025, carries no set-aside designation, demonstrating the company's competitive capability in unrestricted federal procurement. This delivery order is issued...
- The Defense Logistics Agency awarded a delivery order valued at $16,154.36 to DMS Pharmaceutical Group Inc. for the supply of Stelara 90 mg/ml syringes. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, will fulfill this order with an ultimate completion date of October 17, 2025. This delivery order was awarded on a firm fixed-price basis with no set-aside designation, allowing the vendor to compete on an open basis despite its...
- SPE2DB24D9315Indefinite Delivery Contract
- SPE2DB24D9315-SPE2DB26FFWGEDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $16,249.95 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Stelara 90 mg/ml syringes. This firm fixed-price delivery order, issued on October 27, 2025, with an ultimate completion date of November 18, 2025, carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. The award is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (IDC) with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, designated as contract SPE2DR. The PPV-G GEN V represents a $30.3 billion acquisition strategy under which DLA establishes multiple regional prime vendor contractors to support recurring pharmaceutical and medical supply needs of military healthcare facilities worldwide. DMS Pharmaceutical Group's IDC, awarded November 13, 2025, carries a $499.999 billion ceiling value and extends through December 31, 2036, encompassing a 30-month base period with three 30-month option periods. The contractor's established performance across numerous delivery orders for diverse pharmaceutical products—including biologics, specialty medications, vaccines, and medical consumables—demonstrates its capability to fulfill the specialized requirements of the federal military medical system on a global scale.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $16.2k | 10/27/25 |